Newsfeeds - Spark Newswire

3 minute read

News

Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries

Today, 3:20 PM

Advancing its mission to expand access to genetic testing, Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today launched a new version of its market-leading MyRisk Hereditary

MYGN

6 minute read

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs

By Shanthi Rexaline

Today, 3:20 PM

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.

ABUS

16 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For June 15, 2021

By Benzinga Insights

Today, 3:20 PM

ACRS

1 minute read

Raymond James Initiates Coverage On Myriad Genetics with Market Perform Rating

By Benzinga Newsdesk

Today, 3:20 PM

Raymond James analyst Andrew Cooper initiates coverage on Myriad Genetics (NASDAQ:MYGN) with a Market Perform rating.

MYGN

10 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For June 3, 2021

By Benzinga Insights

Today, 3:20 PM

ADC

1 minute read

Goldman Sachs Initiates Coverage On Myriad Genetics with Sell Rating, Announces Price Target of $25

By Benzinga Newsdesk

Today, 3:20 PM

Goldman Sachs analyst Matthew Sykes initiates coverage on Myriad Genetics (NASDAQ:MYGN) with a Sell rating and announces Price Target of $25.

MYGN

5 minute read

Uncategorized

70 Biggest Movers From Yesterday

By Lisa Levin

Today, 3:20 PM

Gainers Nemaura Medical Inc. (NASDAQ: NMRD) shares surged 135.3% to close at $11.06 on Wednesday after the company receipt of a purchase order for 5,000 sugarBEAT transmitters and 200,000 sugarBEAT sensors from its U.K. licensee, DB Ethitronix Ltd.

ADMP

1 minute read

Uncategorized

Recap: Myriad Genetics Q3 Earnings

By Benzinga Insights

Today, 3:20 PM

Shares of Myriad Genetics (NASDAQ:MYGN) remained flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 25.00% over the past year to ($0.06), which beat the estimate of ($0.14).

MYGN

2 minute read

Uncategorized

Labcorp to Acquire Myriad Autoimmune’s Vectra Testing Business From Myriad Genetics; No Terms Disclosed

By Benzinga Newsdesk

Today, 3:20 PM

Labcorp (NYSE:LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire select operating assets and intellectual property (IP) from Myriad Genetics'

8 minute read

Uncategorized

Earnings Scheduled For May 3, 2021

By Benzinga Insights

Today, 3:20 PM

Companies Reporting Before The Bell • Scienjoy Holding (NASDAQ:SJ) is estimated to report quarterly earnings at $0.58 per share on revenue of $540.11 million.

ADC